Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Merus (MRUS), Ginkgo Bioworks Holdings (DNA) and Embecta Corporation (EMBC)

Tipranks - Tipranks - Sat May 24, 2025

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Merus (MRUS – Research Report), Ginkgo Bioworks Holdings (DNA – Research Report) and Embecta Corporation (EMBC – Research Report).

Confident Investing Starts Here:

Merus (MRUS)

In a report released yesterday, Charles Zhu from LifeSci Capital maintained a Buy rating on Merus, with a price target of $110.00. The company’s shares closed last Thursday at $41.60, close to its 52-week low of $37.77.

According to TipRanks.com, Zhu is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.8% and a 32.4% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Mersana Therapeutics, Protara Therapeutics, and Repare Therapeutics. ;'>

Currently, the analyst consensus on Merus is a Strong Buy with an average price target of $88.58, representing a 108.6% upside. In a report issued on May 7, Leerink Partners also maintained a Buy rating on the stock with a $88.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Ginkgo Bioworks Holdings (DNA)

In a report released yesterday, Mark Massaro from BTIG reiterated a Sell rating on Ginkgo Bioworks Holdings, with a price target of $6.00. The company’s shares closed last Thursday at $6.85, close to its 52-week low of $5.26.

According to TipRanks.com, Massaro has 0 stars on 0-5 stars ranking scale with an average return of -9.5% and a 30.3% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Castle Biosciences, and Idexx Laboratories. ;'>

Currently, the analyst consensus on Ginkgo Bioworks Holdings is a Moderate Sell with an average price target of $9.17, which is a 25.3% upside from current levels. In a report issued on May 7, William Blair also maintained a Sell rating on the stock.

Embecta Corporation (EMBC)

In a report released yesterday, Marie Thibault from BTIG reiterated a Buy rating on Embecta Corporation, with a price target of $25.00. The company’s shares closed last Thursday at $10.51, close to its 52-week low of $9.93.

According to TipRanks.com, Thibault is a 4-star analyst with an average return of 3.0% and a 40.9% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Orchestra BioMed Holdings, and Irhythm Technologies. ;'>

Currently, the analyst consensus on Embecta Corporation is a Moderate Buy with an average price target of $18.67.

Read More on MRUS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).